Recent Updates
Recently added Catalysts
BIOA Negative Sentiment Score: 20/100

BioAge Labs, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights – BIOA

Key Takeaway: BioAge Labs, Inc. is facing a lawsuit over alleged securities law violations following the discontinuation of its STRIDES Phase 2 trial for azelaprag. The trial was halted due to safety concerns involving elevated liver transaminase levels in participants. This announcement caused a significant drop in the company's stock price, falling sharply from $20.09 to $4.65. Shareholders impacted during the IPO class period are encouraged to register for potential lead plaintiff status by March 10, 2025.

Market Sentiment Analysis

CONCERNS & RISKS

  • BioAge Labs has been sued for securities law violations.
  • The company discontinued its STRIDES Phase 2 trial for azelaprag due to safety concerns.
  • The stock price plummeted from $20.09 to $4.65 following the announcement of trial discontinuation.

Full Press Release Details

NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of BioAge Labs, Inc. (NASDAQ: BIOA).
Shareholders who purchased shares of BIOA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: This lawsuit is on behalf of all shareholders that purchased stock pursuant and/or traceable to BioAge’s registration statement for the initial public offering held on or about September 26, 2024.
ALLEGATIONS: According to the complaint, on December 6, 2024, BioAge announced that it would discontinue the ongoing STRIDES Phase 2 trial for azelaprag, its lead product candidate, citing safety concerns over elevated liver transaminase levels in participants. This came as a surprise because, at the time of its IPO less than three months earlier, BioAge highlighted azelaprag's potential in patients undergoing obesity therapy with incretin drugs. Following this news, BioAge’s stock price declined from $20.09 per share on December 6, 2024 to $4.65 per share on December 7, 2024.
DEADLINE: March 10, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/bioage-labs-inc-loss-submission-form/?id=123872&from=3
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of BIOA during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is March 10, 2025. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
15 West 38th Street, 12th floor
Phone: (646) 453-8903

Tags

Frequently Asked Questions

What is the class period for the BioAge Labs lawsuit?

The class period covers all shares purchased on or around September 26, 2024.

Why is BioAge Labs being sued?

The lawsuit alleges that BioAge misled investors regarding safety issues with azelaprag.

What happened to BioAge's stock price recently?

After announcing the trial discontinuation, the stock fell from $20.09 to $4.65.

When is the deadline to register for the class action?

The deadline to register is March 10, 2025.

Do I need to be a lead plaintiff to participate?

No, being a lead plaintiff is not necessary to be part of the recovery.

Last updated: Jan 21, 2025